Literature DB >> 23568523

Riboflavin-targeted polymer conjugates for breast tumor delivery.

Lisa M Bareford1, Brittany R Avaritt, Hamidreza Ghandehari, Anjan Nan, Peter W Swaan.   

Abstract

PURPOSE: In breast cancer, a significant decrease in riboflavin (RF) serum levels and increase in RF carrier protein occurs, indicating a potential role of RF in disease progression. To evaluate RF's ability to serve as a targeting agent, mitomycin C (MMC)-conjugated N-(2-hydroxypropyl)methacrylamide (HPMA) copolymers were synthesized and targeted to the RF internalization pathway in human breast cancer cells.
METHODS: Competitive uptake studies were used to determine specificity of RF-targeted conjugates, and an MTT assay established the IC₅₀ for the conjugates. Endocytic mechanisms were investigated by confocal microscopy.
RESULTS: Studies revealed a high-affinity endocytic mechanism for RF-specific internalization of fluorescently-labeled conjugates in both MCF-7 and SKBR-3 cells, whereas folic acid-mediated endocytosis showed high specificity only in SKBR-3 cells. MMC internalization was significantly higher following nontargeted and RF-targeted MMC-conjugate administration compared to that of free MMC. Cytotoxic analysis illustrated potent IC₅₀ values for RF-targeted MMC conjugates similar to free MMC. Maximum nuclear accumulation of MMC resulted from lysosomal release from RF-targeted and nontargeted MMC-conjugates following 6 h incubations, unlike that of free MMC seen within 10 min.
CONCLUSION: Targeting polymer-MMC conjugates to the RF internalization pathway in breast cancer cells enabled an increase in MMC uptake and nuclear localization, resulting in potent cytotoxic activity.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23568523     DOI: 10.1007/s11095-013-1024-5

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  45 in total

Review 1.  Polymeric prodrugs.

Authors:  K Hoste; K De Winne; E Schacht
Journal:  Int J Pharm       Date:  2004-06-11       Impact factor: 5.875

Review 2.  Intracellular targeting of polymer-bound drugs for cancer chemotherapy.

Authors:  Aparna Nori; Jindrich Kopecek
Journal:  Adv Drug Deliv Rev       Date:  2004-12-24       Impact factor: 15.470

3.  DNA alkylation by enzyme-activated mitomycin C.

Authors:  S S Pan; T Iracki; N R Bachur
Journal:  Mol Pharmacol       Date:  1986-06       Impact factor: 4.436

4.  Receptor-targeted gene delivery via folate-conjugated polyethylenimine.

Authors:  W Guo; R L Lee
Journal:  AAPS PharmSci       Date:  1999

5.  Cytoskeletal scaffolds regulate riboflavin endocytosis and recycling in placental trophoblasts.

Authors:  Vanessa M D'Souza; Lisa M Bareford; Abhijit Ray; Peter W Swaan
Journal:  J Nutr Biochem       Date:  2006-03-24       Impact factor: 6.048

6.  Poly(ethylene glycol)-poly(ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates.

Authors:  Lars Andersson; John Davies; Ruth Duncan; Paolo Ferruti; Jayne Ford; Samantha Kneller; Raniero Mendichi; Gianfranco Pasut; Oddone Schiavon; Clive Summerford; Anders Tirk; Francesco M Veronese; Veronica Vincenzi; Gefei Wu
Journal:  Biomacromolecules       Date:  2005 Mar-Apr       Impact factor: 6.988

7.  Riboflavin carrier protein: a serum and tissue marker for breast carcinoma.

Authors:  A A Karande; L Sridhar; K S Gopinath; P R Adiga
Journal:  Int J Cancer       Date:  2001-09-20       Impact factor: 7.396

Review 8.  The folate receptor: what does it promise in tissue-targeted therapeutics?

Authors:  Marcela D'Alincourt Salazar; Manohar Ratnam
Journal:  Cancer Metastasis Rev       Date:  2007-03       Impact factor: 9.264

9.  Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay.

Authors:  Nikki Parker; Mary Jo Turk; Elaine Westrick; Jeffrey D Lewis; Philip S Low; Christopher P Leamon
Journal:  Anal Biochem       Date:  2005-03-15       Impact factor: 3.365

10.  Serum transcobalamin II levels in breast carcinoma patients.

Authors:  B Rachmilewitz; A Sulkes; M Rachmilewitz; Z Fuks
Journal:  Isr J Med Sci       Date:  1981 Sep-Oct
View more
  6 in total

1.  Riboflavin photoactivation by upconversion nanoparticles for cancer treatment.

Authors:  E V Khaydukov; K E Mironova; V A Semchishen; A N Generalova; A V Nechaev; D A Khochenkov; E V Stepanova; O I Lebedev; A V Zvyagin; S M Deyev; V Ya Panchenko
Journal:  Sci Rep       Date:  2016-10-12       Impact factor: 4.379

2.  Supramolecular Host-Guest Chemistry-Based Folate/Riboflavin Functionalization and Cancer Cell Labeling of Nanoparticles.

Authors:  Suman Pal; Chumki Dalal; Nikhil R Jana
Journal:  ACS Omega       Date:  2017-12-14

3.  Evaluation of Riboflavin Transporters as Targets for Drug Delivery and Theranostics.

Authors:  Lisa Bartmann; David Schumacher; Saskia von Stillfried; Marieke Sternkopf; Setareh Alampour-Rajabi; Marc A M J van Zandvoort; Fabian Kiessling; Zhuojun Wu
Journal:  Front Pharmacol       Date:  2019-02-06       Impact factor: 5.810

4.  Photodynamic therapy of melanoma by blue-light photoactivation of flavin mononucleotide.

Authors:  R A Akasov; N V Sholina; D A Khochenkov; A V Alova; P V Gorelkin; A S Erofeev; A N Generalova; E V Khaydukov
Journal:  Sci Rep       Date:  2019-07-04       Impact factor: 4.379

Review 5.  Riboflavin-Targeted Drug Delivery.

Authors:  Milita Darguzyte; Natascha Drude; Twan Lammers; Fabian Kiessling
Journal:  Cancers (Basel)       Date:  2020-01-27       Impact factor: 6.639

6.  Riboflavin-citrate conjugate multicore SPIONs with enhanced magnetic responses and cellular uptake in breast cancer cells.

Authors:  Wid Mekseriwattana; Pablo Guardia; Beatriz Torres Herrero; Jesus M de la Fuente; Chutima Kuhakarn; Anna Roig; Kanlaya Prapainop Katewongsa
Journal:  Nanoscale Adv       Date:  2022-03-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.